Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Kymera Therapeutics (KYMR) Preferred Shares Issued (2019 - 2020)

Kymera Therapeutics (KYMR) has disclosed Preferred Shares Issued for 1 consecutive years, with -$83.4 million as the latest value for Q3 2020.

For Q3 2020, Preferred Shares Issued changed N/A year-over-year to -$83.4 million; the TTM value through Dec 2020 reached $4.8 million, changed N/A, while the annual FY2020 figure was $4.8 million, 65.78% down from the prior year.
Preferred Shares Issued hit -$83.4 million in Q3 2020 for Kymera Therapeutics, down from -$19000.0 in the prior quarter.
Across five years, Preferred Shares Issued topped out at $88.2 million in Q1 2020 and bottomed at -$83.4 million in Q3 2020.